Chronic Spontaneous Urticaria Market Is Anticipated to Progress at a CAGR of 14.96% in the 7MM for the Study Period of 2019-32, Estimates DelveInsight

The current understanding of Chronic Spontaneous Urticaria has greatly improved in recent decades, leading to rising awareness, improved management, better outcomes, as well as the launch of emerging Chronic Spontaneous Urticaria therapies is expected to drive Chronic Spontaneous Urticaria market. The current market is dominated by therapies such as antihistamines and corticosteroids, this landscape is anticipated to disrupt post the launch of emerging therapies including monoclonal antibiotics.

LAS VEGAS, April 25, 2022 /PRNewswire/ -- DelveInsight's Chronic Spontaneous Urticaria  Market Insights report proffers a detailed comprehension of Chronic Spontaneous Urticaria market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Chronic Spontaneous Urticaria market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Some of the salient features from the Chronic Spontaneous Urticaria Market Report: 

• The Chronic Spontaneous Urticaria market size in the 7MM is expected to reach around USD 7,664.5 million by 2032 growing at a CAGR of 14.96% for the study period (2019-2032).
• Key pharmaceutical Chronic Spontaneous Urticaria companies such as Roche, Novartis, Sanofi Pharmaceutical, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company, Amgen, Celldex Therapeutics, GI Innovation, Celltrion, Stero Biotechs, Gilead Sciences, Eden Biologics, Regeneron, UCB Biopharma, Genentech, are reported to bring a significant shift in the Chronic Spontaneous Urticaria market 
• The Chronic Spontaneous Urticaria emerging therapies that are expected to launch in the forecast period include Ligelizumab, Fenebrutinib, Dupilumab, Tezepelumab, CDX-0159, GI-301, and others.
• Delveinsight analyses that extensive research and development along with the expected product launch and approved emerging therapies will significantly impact the growth of the Chronic Spontaneous Urticaria market during the forecast period.
• Age plays an important role in the case of Chronic Spontaneous Urticaria as it is observed to be more common in older adults. According to DelveInsight's analysis, CSU is more prominent in females than in comparison to males.

For further information on market impact by therapies, download Chronic Spontaneous Urticaria market sample @ Chronic Spontaneous Urticaria Therapeutic Scenario

Chronic Spontaneous Urticaria Overview

Chronic Spontaneous Urticaria (CSU) or Chronic Idiopathic Urticaria (CIU) is defined as persistent symptoms of urticaria for 6 weeks or more. It is a distressing skin condition or an allergic reaction that causes red, swollen, itchy, and sometimes painful hives or "wheals" on the skin. It is associated with autoimmunity in almost half of the cases, but the remaining cases still remain "idiopathic," and all are considered spontaneous. Therefore, the term Chronic Spontaneous Urticaria has been employed to indicate chronic urticaria that is endogenous and is independent of any external physical stimulus, which is conceptually helpful and does not imply knowing or not knowing the cause. Chronic Spontaneous Urticaria symptoms include pruritus, wheals, and angioedema.

Chronic Spontaneous Urticaria diagnosis is based on clinical history, physical examination, and the evaluation of some specific factors that aggravate CSU in a substantial subset of patients.

Chronic Spontaneous Urticaria Epidemiology Segmentation

DelveInsight's analysis indicates that in the 7MM most prevalent Chronic Spontaneous Urticaria cases were found to be in the United States whereas in Japan there were the least CSU prevalent cases. Also, the prevalence of the CSU is reportedly varied among the age groups.

The Chronic Spontaneous Urticaria Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into

• Total Prevalent cases of Chronic Spontaneous Urticaria
• Gender-Specific cases of Chronic Spontaneous Urticaria
• Age-Specific cases of Chronic Spontaneous Urticaria
• Total Diagnosed and Treatable Prevalent cases of Chronic Spontaneous Urticaria

Keen to learn how Chronic Spontaneous Urticaria Epidemiological Trends are going to appear in 2032 for the 7 MM, Download @ Chronic Spontaneous Urticaria Epidemiological Insights

Chronic Spontaneous Urticaria Market Outlook

Currently, the primary principle of Chronic Spontaneous Urticaria treatment is to eliminate symptoms, including pruritus, wheals, and angioedema. The treatment plan for Chronic Spontaneous Urticaria focuses on the treatment of the identifiable cause, avoidance of aggravating factors, and antihistamines trial. Topical lotions in the form of calamine lotion, menthol with aqueous cream, and crotamiton lotion are useful soothing agents in the treatment. There are also few FDA-approved therapies for Chronic Spontaneous Urticaria treatment such as XOLAIR when H1 Antihistamines are not enough. The first-line management of acute or chronic urticaria is focused on the use of H1 antihistamines, leukotriene antagonists, and/or H2 receptor antagonists. Whereas, Xolair (omalizumab) is the first biologic medicine and first targeted therapy approved by the FDA for Chronic Spontaneous Urticaria treatment.

Apart from these, there are several other therapeutic options available in the market which have not been included in the guideline which includes dapsone, anticoagulants, methotrexate, azathioprine, mycophenolate mofetil, Cyclosporine A, and biologics including intravenous immunoglobulins (IVIGs), rituximab, and adalimumab.

The Chronic Spontaneous Urticaria market has a promising outlook with many emerging therapies in the pipeline such as Ligelizumab (QGE031) currently being investigated by Novartis, which is a new high-affinity humanized monoclonal anti-IgE antibody and aims to become first-choice biologic after antihistamine therapy. Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in Chronic Spontaneous Urticaria in patients with an inadequate response to H1-antihistamines. Remibrutinib (LOU064) is another emerging drug being studied by Novartis and is an inhibitor of the Burton Tyrosine Kinase (BTK) protein. Currently, LOU064 is being tested in Phase II clinical studies for Chronic Spontaneous Urticaria, Asthma, and Sjorgen's Syndrome. Some other emerging therapies include Dupilumab (DUPIXENT) investigated by Sanofi/ Regeneron, UB-221 from United BioPharma, Tezepelumab from Amgen, CDX-0159 from Celldex Therapeutics, and many others.

Discover more about therapy set to grab substantial Chronic Spontaneous Urticaria market share @ Chronic Spontaneous Urticaria Market Landscape

 Chronic Spontaneous Urticaria Pipeline Therapies and Key Companies

• Ligelizumab: Novartis
• Remibrutinib (LOU064): Novartis
• Tezepelumab: Amgen
• CDX-0159: Celldex Therapeutics
• GI-301: GI Innovation
• Dupilumab (DUPIXENT): Sanofi/ Regeneron
• UB-221: United BioPharma

To know about more pipeline therapies covered in the report, visit @ Chronic Spontaneous Urticaria Pipeline Analysis, Clinical Trials, and Emerging Therapies 

Chronic Spontaneous Urticaria Market Dynamics

The Chronic Spontaneous Urticaria market looks extremely promising with the success of novel therapies in the treatment landscape and it can significantly impact treatment algorithms in the future. Also, in the coming days, the competitive landscape for the Chronic Spontaneous Urticaria (CSU) market is set to change due to improvements in the diagnosis methodologies, raising awareness of the diseases, and incremental healthcare spending across the world. In addition to certain other factors such as the increase in research and development activities, major players are involved in developing therapies, anticipated increase in market size will significantly impact the Chronic Spontaneous Urticaria market in the coming years.

On the contrary aspects such as economic burden on patients, lack of understanding of disease pathology, approaching a patent cliff, and treatment side effects with currently available Chronic Spontaneous Urticaria treatment therapies may all serve as an obstruction for the Chronic Spontaneous Urticaria market opportunities.

Know which therapy is expected to score the touchdown first @ Chronic Spontaneous Urticaria Market Landscape and Forecast

Scope of the Chronic Spontaneous Urticaria Market Report

• Study Period: 2019-32
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Spontaneous Urticaria Companies: Roche, Novartis, Sanofi Pharmaceutical, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company, Amgen, Celldex Therapeutics, GI Innovation, Celltrion, Stero Biotechs, Gilead Sciences, Eden Biologics, Regeneron, UCB Biopharma, Genentech
• Key Chronic Spontaneous Urticaria Pipeline Therapies: Ligelizumab, Fenebrutinib, Dupilumab, Tezepelumab, CDX-0159, GI-301
• Chronic Spontaneous Urticaria Therapeutic Assessment:  Chronic Spontaneous Urticaria current marketed and emerging therapies
• Chronic Spontaneous Urticaria Market Dynamics:  Chronic Spontaneous Urticaria market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs
• KOL's views
• Analyst's views
• Chronic Spontaneous Urticaria Market Access and Reimbursement

Request for a Webex demo of the report @ Chronic Spontaneous Urticaria Therapeutics Market

Table of Contents 

Get in touch with our Business executive @ Chronic Spontaneous Urticaria Market Analysis 

Related Reports

Chronic Spontaneous Urticaria Pipeline

DelveInsight's, "Chronic Spontaneous Urticaria Pipeline Insight, 2022," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Spontaneous Urticaria pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products, and key Chronic Spontaneous Urticaria companies such as Roche, Novartis, Sanofi Pharmaceutical, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company, and many others.

Chronic Spontaneous Urticaria (CSU) Epidemiology 

DelveInsight's "Chronic Spontaneous Urticaria (CSU) Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Chronic Spontaneous Urticaria (CSU) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Allergic Rhinitis Pipeline 

DelveInsight's, " Allergic Rhinitis Pipeline Insight, 2021," report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in the Allergic Rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key Allergic Rhinitis companies involved such as Abdi Ibrahim Pharmaceutical, Allergy Therapeutics, Regeneron Pharmaceuticals, Laboratorios LETI, ALK-Abello, Advagene Biopharma, CSPC ZhongQi Pharmaceutical Technology, Array BioPharma, Immunotek and many others.

Chronic Urticaria Or Hives Pipeline

"Chronic Urticaria Or Hives Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Urticaria Or Hives market. A detailed picture of the Chronic Urticaria Or Hives pipeline landscape is provided, which includes the disease overview and Chronic Urticaria Or Hives treatment guidelines.

Allergic Rhinitis Epidemiology

DelveInsight's ' Allergic Rhinitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Allergic Rhinitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Urticaria Or Hives Market

DelveInsight's "Urticaria Or Hives Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Urticaria Or Hives, historical and forecasted epidemiology as well as the Urticaria Or Hives market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Seasonal Allergic Rhinitis Market 

DelveInsight's " Seasonal Allergic Rhinitis Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Seasonal Allergic Rhinitis, historical and forecasted epidemiology, as well as the Seasonal Allergic Rhinitis market trends, market drivers, market barriers and key Seasonal Allergic Rhinitis companies, involved such as Regeneron Pharmaceuticals, AOBiome, Emergo Therapeutics, Inmunotek, Novartis Pharmaceuticals, ALK-Abello, Torii Pharmaceutical and Stallergenes Greer

Browse Through Our Blog Posts

• Chronic Spontaneous Urticaria Market Infographics
• Anaphylaxis: A Rare Disease
• 8 Of The Most Common Foods Allergies – Do You Have One?

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg